Figure 3
From: Design of combination therapy for engineered bacterial therapeutics in non-small cell lung cancer
Characterizing NSCLC’s response to bacterial therapeutics and designing combination therapies. (a) Schematic of the third part of the pipeline to characterize the NSCLC’s response to S. typhimurium -secreted theta toxin, using RNA sequencing, bioinformatic analysis, designing and testing combination treatment regime in vitro. (b) Gene Set Enrichment Analysis (GSEA) plots (representatives of 3 gene sets) from analyzing Next Gen RNA-sequencing data of 2 NSCLC spheroids, H460 and H1819 co-cultured with live S. typhimurium expressing θ toxin (Stθ) and GFP compared to spheroids with live Salmonella producing only GFP (n = 3). (c) Viability of 2 NSCLC spheroids, H460 and H1819, treated with 7 small molecule inhibitors (MK2206, AZD7762, Pemetrexed, IWR-1, Paclitaxel, SCH772984 and Selumetinib, targeting specific signaling identified by GSEA, under 3 treatment conditions: (1) Drug alone, (2) Drug and bacterially secreted θ (Stθ) in co-culture, (3) Drug and lysates of S. typhimurium producing θ toxin (n = 3, error bars represent standard deviation). Drug concentrations are in μM unit.
